The Rigid Patient
A 24-year-old man with a history of schizophrenia presented with altered mental status. His mother said he had become more catatonic and rigid over the previous two days. She reported that he was prescribed Abilify 5 mg by mouth daily for three years, but a long-acting depot of Abilify 400 mg had been administered two days before by court order. His vital signs include a heart rate of 120 bpm, blood pressure 140/90 mm Hg, temperature 38.5°C, respiratory rate is 14 bpm, and SPO2 is 98% on room air. The patient is alert and diaphoretic. Pupils are 3 mm. Cogwheeling, rigidity, and two beats of ankle clonus are also o...
Source: The Tox Cave - June 2, 2016 Category: Emergency Medicine Tags: Blog Posts Source Type: blogs
A New, and Huge ($2.2 Billion) Settlement for Johnson and Johnson, but "No Individuals were Charged with Wrongdoing"
The march of legal settlements made by big health care organizations has resumed with a bang. As reported in most major media outlets, giant drug/ device/ biotechnology company Johnson and Johnson has made a big settlement with the US Department of Justice.The Basics of the SettlementAs reported by Bloomberg / Businessweek, Johnson & Johnson agreed to resolve criminal and civil probes into the marketing of Risperdal, an antipsychotic drug, and other medicines by paying more than $2.2 billion, one of the largest U.S. health-fraud penalties. J&J’s Janssen unit will plead guilty to a misdemeanor criminal ...
Source: Health Care Renewal - November 5, 2013 Category: Health Medicine and Bioethics Commentators Tags: deception kickbacks Johnson and Johnson impunity crime marketing legal settlements Source Type: blogs
The mislead consumers - courtesy of big pharma
I wish to say a big "thank you" to Johnson & Johnson and their marketing departments for misleading so many patients and nursing homes on three of their drugs. For their efforts, they will pay $2.2 billion in fines."The settlement involves the schizophrenia drugs Risperdal and Invega, and the heart failure drug Natrecor, the company and Attorney General Eric Holder said. Johnson & Johnson and two subsidiaries "lined their pockets at the expense of American taxpayers, patients and the private insurance industry," Holder said." You think they would have learned from their $1.2 billion in fines in 2011. Oh ...
Source: Caroline's Breast Cancer Blog - November 5, 2013 Category: Cancer Tags: insurance costs medication pharmaceutical manufacturers scammers Source Type: blogs
The misled consumers - courtesy of big pharma
I wish to say a big "thank you" to Johnson & Johnson and their marketing departments for misleading so many patients and nursing homes on three of their drugs. For their efforts, they will pay $2.2 billion in fines."The settlement involves the schizophrenia drugs Risperdal and Invega, and the heart failure drug Natrecor, the company and Attorney General Eric Holder said. Johnson & Johnson and two subsidiaries "lined their pockets at the expense of American taxpayers, patients and the private insurance industry," Holder said." You think they would have learned from their $1.2 billion in fines in 2011. Oh ...
Source: Caroline's Breast Cancer Blog - November 5, 2013 Category: Cancer Tags: insurance costs medication pharmaceutical manufacturers scammers Source Type: blogs
J&J to pay $2.2B to settle Risperdal marketing allegations
Johnson & Johnson has agreed to pay over $2.2 billion to resolve criminal and civil allegations that the company promoted powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients, the Department of Justice announced on Monday.The agreement is the third-largest settlement with a drugmaker in U.S. history, and the latest in a string of actions against drug companies allegedly putting profits ahead of patients.Justice Department officials alleged that J&J used illegal marketing tactics and kickbacks to persuade physicians and pharmacists to prescribe Risperdal and Invega, both antipsyc...
Source: PharmaGossip - November 5, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Attorney General Eric Holder Delivers Remarks at the Johnson & Johnson Press Conference
Attorney General Eric Holder Delivers Remarks at the Johnson & Johnson Press Conference
~ Monday, November 4, 2013
Good morning – and thank you all for being here. I am joined by Associate Attorney General [Tony] West; Assistant Attorney General for the Civil Division [Stuart] Delery; U.S. Attorney for the Eastern District of Pennsylvania [Zane] Memeger; U.S. Attorney for the District of Massachusetts [Carmen] Ortiz; First Assistant U.S. Attorney for the Northern District of California [Brian] Stretch; and Deputy Inspector General for Investigations at the Department of Health and Human Services [Gary] Cantrell...
Source: PharmaGossip - November 5, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Johnson & Johnson to Pay More Than $2.2 Billion to Resolve Criminal and Civil Investigations - DoJ
Johnson & Johnson to Pay More Than $2.2 Billion to Resolve Criminal and Civil Investigations
Allegations Include Off-label Marketing and Kickbacks to Doctors and Pharmacists
WASHINGTON - Global health care giant Johnson & Johnson (J&J) and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by the Food and Drug Administration (FDA) and payment of kickbacks to physicians and to the nation’s largest long-term care phar...
Source: PharmaGossip - November 5, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Johnson & Johnson to Pay More Than $2.2 Billion to Resolve Criminal and Civil Investigations
Despite the FDA warnings and increased health risks, from 1999 through 2005, Janssen aggressively marketed Risperdal to control behavioral disturbances in dementia patients through an “ElderCare sales force” designed to target nursing homes and doctors who treated the elderly.
Allegations Include Off-label Marketing and Kickbacks to Doctors and Pharmacists.
+Alzheimer's Reading Room
Global health care giant Johnson & Johnson (J&J) and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natr...
Source: Alzheimer's Reading Room, The - November 5, 2013 Category: Dementia Authors: Bob DeMarco Source Type: blogs
Johnson and Johnson 2013 Settlement and Corporate Integrity Agreement
On November 4, 2013, the Department of Justice (DOJ) announced that Johnson & Johnson (J&J) and its pharmaceutical subsidiaries signed settlement agreements to pay more than $2.2 billion to resolve criminal and civil investigations into unapproved, or "off-label," promotion of three drugs and alleged kickbacks to physicians and nursing home pharmacies over a ten-year period. In 2012, we reported on the largest health care fraud settlement in U.S. history: $3 billion paid by GlaxoSmithKline.
According to the Associated Press, the J&J global settlement is the third-largest health care fraud settlement in U.S...
Source: Policy and Medicine - November 5, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs
Strict Conflict of interest Policies at Academic Medical Centers Lead to Prescribing Older Generic Drugs
The objective of the study was to “examine the effect of attending a medical school with an active policy on restricting gifts from representatives of pharmaceutical and device industries on subsequent prescribing behavior.”
Interestingly, the study was funded by the National Institute of Mental Health (NIMH), the National Institute on Aging, the American Federation on Aging, and NIH. Which we all know means the study is completely unbiased.
Specifically, the authors looked at the probability that a physician would prescribe a newly marketed medication over existing alternatives of three psychotropic classes:...
Source: Policy and Medicine - February 28, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs
